Nanotheranostics in Obesity and Diabetes: Dual Role in Early Detection and Precision Therapy

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

                                                                                               ABSTRACT
Obesity and type 2 diabetes (T2D) arise from complex, tissue-specific pathologies spanning adipose inflammation, ectopic lipid deposition, hepatic insulin resistance, and microvascular dysfunction. Conventional diagnostics detect late-stage complications and provide limited spatial resolution of disease activity, while therapeutics often lack tissue selectivity and dynamic control. Nanotheranostics as a single platform that integrate targeted imaging and therapy offers a route to earlier detection and precision intervention. Engineered nanoparticles can home to metabolically diseased tissues, amplify multimodal imaging signals, and release drugs in response to biochemical cues such as pH, enzymes, or redox gradients. By coupling quantification and treatment within the same construct, nanotheranostics enable dose individualization, on-treatment monitoring,
and adaptive regimens guided by imaging readouts. This review outlines biological rationales for theranostic targeting in metabolic disease; surveys contrast chemistries and imaging modalities suited to adipose, liver, pancreas, muscle, and vasculature; details stimuli-responsive designs that synchronize drug release with pathologic microenvironments; and examines safety, manufacturability, and regulatory pathways. We propose
clinical trial frameworks that incorporate quantitative imaging endpoints with glycemic and cardiometabolic outcomes, positioning nanotheranostics as complementary to incretins, SGLT2 inhibitors, and lifestyle interventions. If translated responsibly, nanotheranostics could shift obesity and T2D care from reactive management to proactive, image-guided precision therapy.

Keywords: nanotheranostics; metabolic imaging; targeted nanoparticles; adipose inflammation; insulin
resistance; precision medicine; type 2 diabetes; image-guided therapy.

CITE AS: Katu Amina H. (2026). Nanotheranostics in Obesity and Diabetes: Dual Role in Early Detection and Precision Therapy.
NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.102108